Value of genetic testing in the management of the congenital long QT syndrome;Apports de la génétique dans la prise en charge du syndrome du QT long congénital

Archives des Maladies du Coeur et des Vaisseaux

Volumn 96, Issue 5, 2003, Pages 539-547

  Lupoglazoff, J M ^a,b   Denjoy, I ^a,c   Guicheney, P ^b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; APRINDINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOQUINE; CHLORPROMAZINE; CIBENZOLINE; CLARITHROMYCIN; CORBIANOX; DIHYDROQUINIDINE; DISOPYRAMIDE; DIURETIC AGENT; DOXEPIN; DRALEPTAN; DROPERIDOL; ERYTHROMYCIN; EXACOR; FLECAINIDE; FLECAINIDE ACETATE; FLUOXETINE; HALOPERIDOL; IBUTILIDE; IBUTILIDE FUMARATE; IMIPRAMINE; ISORYTHM; ITRACONAZOLE; KETOCONAZOLE; MAPROTILINE; PHENOTHIAZINE; PIMOZIDE; POTASSIUM CHANNEL; PROPAFENONE; QUINIDINE; QUINIDINE ARABOGALACTAN SULFATE; QUINIDRULE; RHEOBRAL; RISPERIDONE; SOTALOL; SULTOPRIDE; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; VINCAFOR; VINCVARUTINE;

ACTION POTENTIAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; EVALUATION; FAMILY; GENE; GENETIC ANALYSIS; GENETIC CODE; HEARING IMPAIRMENT; HEART VENTRICLE FIBRILLATION; HETEROZYGOTE; HOLTER MONITORING; HOMOZYGOTE; HUMAN; LONG QT SYNDROME; PROGNOSIS; PROPHYLAXIS; QT INTERVAL; REVIEW; RISK; SUDDEN DEATH; SYNCOPE; SYNDROME DELINEATION; TORSADE DES POINTES;

ALGORITHMS; ELECTROCARDIOGRAPHY; GENETIC SCREENING; GENOTYPE; HUMANS; LONG QT SYNDROME; MUTATION; PHENOTYPE; PROGNOSIS;

EID: 0038778472     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Chiang CE, Roden DM. The long QT syndromes: genetic basis and c clinical implications. J Am Coll Cardiol 2000; 36: 1-12.
2. Splawski I, Shen J, Timothy K et al. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation 2000; 102: 1178-85.
3. Roden D, Spooner P. Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Eletrophysiol 1999; 10: T664-83.
4. Ackerman MJ, Siu B, Sturner W et al. Post-mortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA 2001; 286: 2264-9.
5. Schwartz PJ, Stramba-Badiale M, Segantini A et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1709-14.
6. Schwartz PJ, Priori SG, Dumaine R et al. A molecular link between the sudden death syndrome and the long QT syndrome. N Engl J Med 2000; 343: 262-7.
7. Wedekind H, Smits J, Schulze-Bahr E et al. De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation 2001; 104: 1158-64.
8. Le Heuzey JY, Davy JM, Weissenburger J et al. Intervalle QT et médicaments: recommandations pour la prescription des médicaments chez les patients atteints du SQTL congenital. Arch Mal Cœur 1998; 91: 59-66.
9. Chen Q, Kirsch G, Zhang D et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293-6.
10. Schott JJ, Alshinawi C, Kyndt F et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23: 20-1.
11. Tan HL, Bink-Boelkens MT, Bezzina C et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001; 409: 1043-7.
12. Bezzina C, Veldkomp M, van Den Berg M et al. A single sodium channel mutation causing both long QT and Brugada syndromes. Circ Res 1999; 85: 1206-13.
13. Clancy CE, Rudy Y. Na+ channel mutation that causes Brugada and long QT syndrome phenotypes. Circulation 2002; 101: 1208-14.
14. Kyndt F, Probst V, Potet F et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
15. Davignon A, Rautaharju P, Boisselle E, Soumis F, Megelas M, Choquette A. Normal ECG standards for infants and children. Pediatr Cardiol 1979/80; 1: 123-31.
16. Schwartz PJ, Garson Jr A, Paul T et al. Guidelines for the interpretation of the neonatal electrocardiogram. Eur Heart J 2002; 23: 1329-44.
17. Rijnbeek PR, Witsenburg M, Schrama E, Hess J, Kors JA. New normal limits for the paediatric electrocardiogrm. Eur Heart J 2001; 22: 702-11.
18. Vincent GM. Role of DNA testing for diagnosis, management and genetic screening in long QT syndrom, hypertrophic cardiomyopathy, and Marfan syndrom. Heart 2001; 86: 12-6.
19. Vincent GM. The heart rate of Romano Ward syndrome patients. Am Heart J 1986; 112: 61-4.
20. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarisation during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol 1999; 34: 823-9.
21. Moss AJ, Schwartz PJ, Crampton RS et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-44.
22. Zareba W, Moss AJ, Schwartz PJ et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998; 339: 960-5.
23. Scott WA, Dick M. Two: one atrioventricular block in infants with congenital long QT syndrome. Am J Cardiol 1987; 60: 1409-10.
24. Weintraub RG, Gow RM, Wilkinson JL. The congenital long QT syndromes in childhood. J Am Coll Cardiol 1990; 16: 674-80.
25. Trippel DL, Parsons MK, Gillette PC. Infants with long-QT syndrome and 2:1 atrioventricular block. Am Heart J 1995; 130: 1130-4.
26. Lupoglazoff JM, Cheav T, Baroudi G et al. Homozygous SCN5A mutation in long-QT syndrome with functional two-toone atrio-ventricular block. Circ Res 2001; 89: e16-e21.
27. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation 1993; 88: 782-4.
28. Donger C, Denjoy I, Berthet M et al. KVLQT1 C-terminal missense mutation causes for forme frustre long QT syndrome. Circulation 1997; 96: 2778-81.
29. Lupoglazoff JM, Denjoy I, Guicheney P, Casasoprana A, Coumel P. Syndrome du QT long congénital. Arch Pediatr 2001; 8: 525-34.
30. Vincent GM, Timothy KW, Fox J, Zhang L. The herited long QT syndrome: from ion channel to bedside. Cardiol Rev 1999; 7: 44-55.
31. Zhang L, Timothy K, Vincent M et al. Spectrum of ST-T wave patterns and repolarization parameters in congenital long QT syndrome. Circulation 2000; 102: 2849-55.
32. Priori S, Barhanin J, Hauer R et al. Genetic and molecular basis of cardiac arrhythmias impact on clinical management parts I and II. Circulation 1999; 99: 518-28.
33. Berthet M, Denjoy I, Donger C et al. C-terminal HERG mutations: the role of hypokaliemia and a KCNQ1 associated mutation in cardiac event occurrence. Circulation 1999; 99: 1464-70.
34. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99: 529-33.
35. Wilde A, Jongbloed RJ, Doevendans PA et al. Auditory stimuli as a trigger for arrhythmic events differenciate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999; 33: 327-32.
36. Moss AJ, Robinson J, Gessman L et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84: 876-9.
37. Schwartz PJ, Priori SG, Spazzolini C et al. Genotype phenotype correlation in the long QT syndrome: specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95
38. Moss AJ, Zareba W, Benhorin J et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-34.
39. Lupoglazoff JM, Denjoy I, Berthet M et al. Notched T waves on Holter recordings in long-QT syndrome: a phenotypic marker of HERG missense mutation carriers. Circulation 2001; 103: 1095-101.
40. Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in Romano-Ward herited syndrome. Am J Cardiol 1991; 68: 498-503.
41. Swan H, Saarilen K, Kontula K, Toivonen L, Viitasalo M. Evaluation of QT interval duration and dispersion and proposed clinical criteria in diagnosis of long QT syndrome in patients with genetically uniform type of LQT1. J Am Coil Cardiol 1998; 32: 486-91.
42. Rashba EJ, Zareba W, Moss AJ. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. Circulation 1998; 97: 451-6.
43. Kimbrough J, Moss A, Zareba W et al. Clinical implications for affected parents and sibblings of probands with long QT syndrome. Circulation 2001; 104: 557-62.
44. Denjoy I, Lupoglazoff JM, Donger C et al. Syndrome du QT long congénital. Apport de la génétique dans l'évaluation pronostique. Arch Mal Cœur 1999; 92: 557-63.
45. Moss AJ, Zareba W, Kaufman ES et al. Increased risk of arrhythmic events in long QT syndrome with mutations in the pore region of the Human Ether-a-go-go-related gene potassium channel. Circulation 2002; 105: 794-9.
46. Khan IA. Long QT syndrome: diagnosis and management. Am Heart J 2002; 143: 7-14.
47. Moss AJ, Zareba W, Hall WJ et al. Effectiveness and limitations of beta-blocker therapy in congenital long QT syndrome. Circulation 2000; 101: 616-23.
48. Compton S, Lux R, Ramsey M et al. Genetically defined therapy of inherited long-QT syndrome correction of abnormal repolarization by potassium. Circulation 1996; 94: 1018-22.